Market closed
Minerva Neurosciences Inc/$NERV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Ticker
$NERV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
8
Website
NERV Metrics
BasicAdvanced
$11M
8.25
$0.19
0.09
-
Price and volume
Market cap
$11M
Beta
0.09
52-week high
$1.91
52-week low
$1.15
Average daily volume
18K
Financial strength
Current ratio
7.85
Quick ratio
7.53
Long term debt to equity
-233.526
Total debt to equity
-233.526
Interest coverage (TTM)
-4.79%
Management effectiveness
Return on assets (TTM)
-29.04%
Return on equity (TTM)
-5.31%
Valuation
Price to earnings (TTM)
8.251
Price to book
-0.43
Price to tangible book (TTM)
-0.27
Price to free cash flow (TTM)
-0.607
Growth
Earnings per share change (TTM)
-104.12%
3-year earnings per share growth (CAGR)
-72.71%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Minerva Neurosciences Inc stock?
Minerva Neurosciences Inc (NERV) has a market cap of $11M as of April 16, 2025.
What is the P/E ratio for Minerva Neurosciences Inc stock?
The price to earnings (P/E) ratio for Minerva Neurosciences Inc (NERV) stock is 8.25 as of April 16, 2025.
Does Minerva Neurosciences Inc stock pay dividends?
No, Minerva Neurosciences Inc (NERV) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Minerva Neurosciences Inc dividend payment date?
Minerva Neurosciences Inc (NERV) stock does not pay dividends to its shareholders.
What is the beta indicator for Minerva Neurosciences Inc?
Minerva Neurosciences Inc (NERV) has a beta rating of 0.09. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.